Concepedia

Xingnian Fu

XF

Statistics

Publications

5

Citations

306

H-Index

5

Active since

2005

Affiliations

Novartis (China)(Current)

Novartis (United States)

Chinese Academy of Sciences

Shanghai Institute of Organic Chemistry

Xingnian Fu is an author at Novartis (China) specializing in biomolecular engineering, organic chemistry, and tumor biology.

Top concepts

Publications per year

2005–2022

5

Publications

5

Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy

Ying Huang, Jeff Zhang, Zhengtian Yu et al. · Journal of Medicinal Chemistry · 2017 · 100 citations · Full text

Total Synthesis of (−)‐Jiadifenin

Yang Yang, Xingnian Fu, Jianwei Chen et al. · Angewandte Chemie International Edition · 2012 · 67 citations · Full text

, , +11

Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase

Andreas Lingel, Martin Sendzik, Ying Huang et al. · Journal of Medicinal Chemistry · 2016 · 56 citations · Full text

, , +21

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies

Ying Huang, Martin Sendzik, Jeff Zhang et al. · Journal of Medicinal Chemistry · 2022 · 49 citations · Full text

Facile Construction of the Pentacyclic Framework of Subincanadine B. Synthesis of 20-Deethylenylated Subincanadine B and 19,20-Dihydrosubincanadine B

Yanqin Liu, Shengjun Luo, Xingnian Fu et al. · Organic Letters · 2005 · 34 citations

1–5 of 5